Literature DB >> 4422361

Rating the presence and severity of opiate dependence.

R I Wang, R L Wiesen, S Lamid, B L Roh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4422361     DOI： 10.1002/cpt1974164653

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  14 in total

1.  Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

Authors:  Maria A Sullivan; Suzanne K Vosburg; Sandra D Comer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-14       Impact factor: 4.530

2.  Deficits in dopamine D(2) receptors and presynaptic dopamine in heroin dependence: commonalities and differences with other types of addiction.

Authors:  Diana Martinez; Phillip A Saccone; Fei Liu; Mark Slifstein; Daria Orlowska; Alex Grassetti; Stephanie Cook; Allegra Broft; Ronald Van Heertum; Sandra D Comer
Journal:  Biol Psychiatry       Date:  2011-10-19       Impact factor: 13.382

Review 3.  Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

4.  Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.

Authors:  Sandra D Comer; Eric D Collins; Herbert D Kleber; Elie S Nuwayser; James H Kerrigan; Marian W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-11-01       Impact factor: 4.530

5.  Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.

Authors:  Sandra D Comer; Verena E Metz; Ziva D Cooper; William J Kowalczyk; Jermaine D Jones; Maria A Sullivan; Jeanne M Manubay; Suzanne K Vosburg; Mary E Smith; Deena Peyser; Phillip A Saccone
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

6.  Changes in cardiac vagal tone as measured by heart rate variability during naloxone-induced opioid withdrawal.

Authors:  Charles J Levin; Jonathan M Wai; Jermaine D Jones; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2019-09-03       Impact factor: 4.492

7.  Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal.

Authors:  L Gallimberti; F Schifano; G Forza; L Miconi; S D Ferrara
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

8.  Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument.

Authors:  D Andrew Tompkins; George E Bigelow; Joseph A Harrison; Rolley E Johnson; Paul J Fudala; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2009-08-03       Impact factor: 4.492

9.  Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone.

Authors:  Jermaine D Jones; Mudassir Mumtaz; Jeanne M Manubay; Shanthi Mogali; Elliana Sherwin; Suky Martinez; Sandra D Comer
Journal:  Pharmacol Biochem Behav       Date:  2019-09-04       Impact factor: 3.533

10.  Naloxone-Induced Withdrawal in Individuals With and Without Fentanyl-Positive Urine Samples.

Authors:  Jermaine D Jones; Elliana Sherwin; Suky Martinez; Sandra D Comer
Journal:  Am J Addict       Date:  2019-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.